Who are Standard-DAPT of Ticagrelor plus aspirin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/standard-dapt-of-ticagrelor-plus-aspirin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Standard-DAPT of Ticagrelor plus aspirin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Standard-DAPT of Ticagrelor plus aspirin (Standard-DAPT of Ticagrelor plus aspirin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor. Area: Cardiovascular.

marketed Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor P2Y12 receptor (ticagrelor); cyclooxygenase-1 (aspirin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Standard-DAPT of Ticagrelor plus aspirin (Standard-DAPT of Ticagrelor plus aspirin) — Second Affiliated Hospital, School of Medicine, Zhejiang University. Ticagrelor and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard-DAPT of Ticagrelor plus aspirin TARGET	Standard-DAPT of Ticagrelor plus aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor	P2Y12 receptor (ticagrelor); cyclooxygenase-1 (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor class)

Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard-DAPT of Ticagrelor plus aspirin — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-dapt-of-ticagrelor-plus-aspirin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab